Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
Identifieur interne : 003647 ( Main/Exploration ); précédent : 003646; suivant : 003648Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
Auteurs : J-J Grob [France] ; M M Amonkar [États-Unis] ; S. Martin-Algarra [Espagne] ; L V Demidov [Russie] ; V. Goodman [États-Unis] ; K. Grotzinger [États-Unis] ; P. Haney [États-Unis] ; E. K Mpgen [Allemagne] ; B. Karaszewska [Pologne] ; C. Mauch [Allemagne] ; W H Miller [Canada] ; M. Millward [Australie] ; B. Mirakhur [États-Unis] ; P. Rutkowski [Pologne] ; V. Chiarion-Sileni [Italie] ; S. Swann [États-Unis] ; A. Hauschild [Allemagne]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- anatomopathologie : Mélanome.
- traitement médicamenteux : Mélanome.
- usage thérapeutique : Antinéoplasiques, Dacarbazine, Imidazoles, Oximes.
- Humains, Métastase tumorale, Qualité de vie.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Dacarbazine, Imidazoles, Oximes.
- drug therapy : Melanoma.
- pathology : Melanoma.
- Humans, Neoplasm Metastasis, Quality of Life.
Abstract
In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P < 0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial.
DOI: 10.1093/annonc/mdu154
PubMed: 24769640
Affiliations:
- Allemagne, Australie, Canada, Espagne, France, Italie, Pologne, Russie, États-Unis
- Bavière, District de Moyenne-Franconie, District fédéral central, Provence-Alpes-Côte d'Azur, Québec, Schleswig-Holstein
- Erlangen, Kiel, Marseille, Montréal, Moscou
- Université McGill
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003670
- to stream PubMed, to step Curation: 003557
- to stream PubMed, to step Checkpoint: 003557
- to stream Ncbi, to step Merge: 001992
- to stream Ncbi, to step Curation: 001992
- to stream Ncbi, to step Checkpoint: 001992
- to stream Main, to step Merge: 003668
- to stream Main, to step Curation: 003647
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.</title><author><name sortKey="Grob, J J" sort="Grob, J J" uniqKey="Grob J" first="J-J" last="Grob">J-J Grob</name><affiliation wicri:level="3"><nlm:affiliation>Aix-Marseille University, APHM, Hôpital Timone, Marseille, France jean-jacques.grob@ap-hm.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>Aix-Marseille University, APHM, Hôpital Timone, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Amonkar, M M" sort="Amonkar, M M" uniqKey="Amonkar M" first="M M" last="Amonkar">M M Amonkar</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="Martin Algarra, S" sort="Martin Algarra, S" uniqKey="Martin Algarra S" first="S" last="Martin-Algarra">S. Martin-Algarra</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Demidov, L V" sort="Demidov, L V" uniqKey="Demidov L" first="L V" last="Demidov">L V Demidov</name><affiliation wicri:level="3"><nlm:affiliation>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow</wicri:regionArea><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Goodman, V" sort="Goodman, V" uniqKey="Goodman V" first="V" last="Goodman">V. Goodman</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="Grotzinger, K" sort="Grotzinger, K" uniqKey="Grotzinger K" first="K" last="Grotzinger">K. Grotzinger</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="Haney, P" sort="Haney, P" uniqKey="Haney P" first="P" last="Haney">P. Haney</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="K Mpgen, E" sort="K Mpgen, E" uniqKey="K Mpgen E" first="E" last="K Mpgen">E. K Mpgen</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen</wicri:regionArea><placeName><settlement type="city">Erlangen</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Moyenne-Franconie</region></placeName></affiliation></author><author><name sortKey="Karaszewska, B" sort="Karaszewska, B" uniqKey="Karaszewska B" first="B" last="Karaszewska">B. Karaszewska</name><affiliation wicri:level="1"><nlm:affiliation>Przychodnia Lekarska KOMED, Konin, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Przychodnia Lekarska KOMED, Konin</wicri:regionArea><wicri:noRegion>Konin</wicri:noRegion></affiliation></author><author><name sortKey="Mauch, C" sort="Mauch, C" uniqKey="Mauch C" first="C" last="Mauch">C. Mauch</name><affiliation wicri:level="1"><nlm:affiliation>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Miller, W H" sort="Miller, W H" uniqKey="Miller W" first="W H" last="Miller">W H Miller</name><affiliation wicri:level="4"><nlm:affiliation>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region><settlement type="city">Montréal</settlement></placeName><orgName type="university">Université McGill</orgName></affiliation></author><author><name sortKey="Millward, M" sort="Millward, M" uniqKey="Millward M" first="M" last="Millward">M. Millward</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Mirakhur, B" sort="Mirakhur, B" uniqKey="Mirakhur B" first="B" last="Mirakhur">B. Mirakhur</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="Rutkowski, P" sort="Rutkowski, P" uniqKey="Rutkowski P" first="P" last="Rutkowski">P. Rutkowski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Chiarion Sileni, V" sort="Chiarion Sileni, V" uniqKey="Chiarion Sileni V" first="V" last="Chiarion-Sileni">V. Chiarion-Sileni</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova</wicri:regionArea><wicri:noRegion>Padova</wicri:noRegion></affiliation></author><author><name sortKey="Swann, S" sort="Swann, S" uniqKey="Swann S" first="S" last="Swann">S. Swann</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24769640</idno><idno type="pmid">24769640</idno><idno type="doi">10.1093/annonc/mdu154</idno><idno type="wicri:Area/PubMed/Corpus">003670</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003670</idno><idno type="wicri:Area/PubMed/Curation">003557</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003557</idno><idno type="wicri:Area/PubMed/Checkpoint">003557</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003557</idno><idno type="wicri:Area/Ncbi/Merge">001992</idno><idno type="wicri:Area/Ncbi/Curation">001992</idno><idno type="wicri:Area/Ncbi/Checkpoint">001992</idno><idno type="wicri:Area/Main/Merge">003668</idno><idno type="wicri:Area/Main/Curation">003647</idno><idno type="wicri:Area/Main/Exploration">003647</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.</title><author><name sortKey="Grob, J J" sort="Grob, J J" uniqKey="Grob J" first="J-J" last="Grob">J-J Grob</name><affiliation wicri:level="3"><nlm:affiliation>Aix-Marseille University, APHM, Hôpital Timone, Marseille, France jean-jacques.grob@ap-hm.fr.</nlm:affiliation><country wicri:rule="url">France</country><wicri:regionArea>Aix-Marseille University, APHM, Hôpital Timone, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Amonkar, M M" sort="Amonkar, M M" uniqKey="Amonkar M" first="M M" last="Amonkar">M M Amonkar</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="Martin Algarra, S" sort="Martin Algarra, S" uniqKey="Martin Algarra S" first="S" last="Martin-Algarra">S. Martin-Algarra</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Demidov, L V" sort="Demidov, L V" uniqKey="Demidov L" first="L V" last="Demidov">L V Demidov</name><affiliation wicri:level="3"><nlm:affiliation>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow</wicri:regionArea><placeName><settlement type="city">Moscou</settlement><region>District fédéral central</region></placeName></affiliation></author><author><name sortKey="Goodman, V" sort="Goodman, V" uniqKey="Goodman V" first="V" last="Goodman">V. Goodman</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="Grotzinger, K" sort="Grotzinger, K" uniqKey="Grotzinger K" first="K" last="Grotzinger">K. Grotzinger</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="Haney, P" sort="Haney, P" uniqKey="Haney P" first="P" last="Haney">P. Haney</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="K Mpgen, E" sort="K Mpgen, E" uniqKey="K Mpgen E" first="E" last="K Mpgen">E. K Mpgen</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen</wicri:regionArea><placeName><settlement type="city">Erlangen</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Moyenne-Franconie</region></placeName></affiliation></author><author><name sortKey="Karaszewska, B" sort="Karaszewska, B" uniqKey="Karaszewska B" first="B" last="Karaszewska">B. Karaszewska</name><affiliation wicri:level="1"><nlm:affiliation>Przychodnia Lekarska KOMED, Konin, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Przychodnia Lekarska KOMED, Konin</wicri:regionArea><wicri:noRegion>Konin</wicri:noRegion></affiliation></author><author><name sortKey="Mauch, C" sort="Mauch, C" uniqKey="Mauch C" first="C" last="Mauch">C. Mauch</name><affiliation wicri:level="1"><nlm:affiliation>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Miller, W H" sort="Miller, W H" uniqKey="Miller W" first="W H" last="Miller">W H Miller</name><affiliation wicri:level="4"><nlm:affiliation>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region><settlement type="city">Montréal</settlement></placeName><orgName type="university">Université McGill</orgName></affiliation></author><author><name sortKey="Millward, M" sort="Millward, M" uniqKey="Millward M" first="M" last="Millward">M. Millward</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Mirakhur, B" sort="Mirakhur, B" uniqKey="Mirakhur B" first="B" last="Mirakhur">B. Mirakhur</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="Rutkowski, P" sort="Rutkowski, P" uniqKey="Rutkowski P" first="P" last="Rutkowski">P. Rutkowski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Chiarion Sileni, V" sort="Chiarion Sileni, V" uniqKey="Chiarion Sileni V" first="V" last="Chiarion-Sileni">V. Chiarion-Sileni</name><affiliation wicri:level="1"><nlm:affiliation>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova</wicri:regionArea><wicri:noRegion>Padova</wicri:noRegion></affiliation></author><author><name sortKey="Swann, S" sort="Swann, S" uniqKey="Swann S" first="S" last="Swann">S. Swann</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Collegeville, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, Collegeville</wicri:regionArea><wicri:noRegion>Collegeville</wicri:noRegion></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (therapeutic use)</term><term>Dacarbazine (therapeutic use)</term><term>Humans</term><term>Imidazoles (therapeutic use)</term><term>Melanoma (drug therapy)</term><term>Melanoma (pathology)</term><term>Neoplasm Metastasis</term><term>Oximes (therapeutic use)</term><term>Quality of Life</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (usage thérapeutique)</term><term>Dacarbazine (usage thérapeutique)</term><term>Humains</term><term>Imidazoles (usage thérapeutique)</term><term>Mélanome (anatomopathologie)</term><term>Mélanome (traitement médicamenteux)</term><term>Métastase tumorale</term><term>Oximes (usage thérapeutique)</term><term>Qualité de vie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Dacarbazine</term><term>Imidazoles</term><term>Oximes</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Dacarbazine</term><term>Imidazoles</term><term>Oximes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Neoplasm Metastasis</term><term>Quality of Life</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Métastase tumorale</term><term>Qualité de vie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P < 0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pologne</li><li>Russie</li><li>États-Unis</li></country><region><li>Bavière</li><li>District de Moyenne-Franconie</li><li>District fédéral central</li><li>Provence-Alpes-Côte d'Azur</li><li>Québec</li><li>Schleswig-Holstein</li></region><settlement><li>Erlangen</li><li>Kiel</li><li>Marseille</li><li>Montréal</li><li>Moscou</li></settlement><orgName><li>Université McGill</li></orgName></list><tree><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Grob, J J" sort="Grob, J J" uniqKey="Grob J" first="J-J" last="Grob">J-J Grob</name></region></country><country name="États-Unis"><noRegion><name sortKey="Amonkar, M M" sort="Amonkar, M M" uniqKey="Amonkar M" first="M M" last="Amonkar">M M Amonkar</name></noRegion><name sortKey="Goodman, V" sort="Goodman, V" uniqKey="Goodman V" first="V" last="Goodman">V. Goodman</name><name sortKey="Grotzinger, K" sort="Grotzinger, K" uniqKey="Grotzinger K" first="K" last="Grotzinger">K. Grotzinger</name><name sortKey="Haney, P" sort="Haney, P" uniqKey="Haney P" first="P" last="Haney">P. Haney</name><name sortKey="Mirakhur, B" sort="Mirakhur, B" uniqKey="Mirakhur B" first="B" last="Mirakhur">B. Mirakhur</name><name sortKey="Swann, S" sort="Swann, S" uniqKey="Swann S" first="S" last="Swann">S. Swann</name></country><country name="Espagne"><noRegion><name sortKey="Martin Algarra, S" sort="Martin Algarra, S" uniqKey="Martin Algarra S" first="S" last="Martin-Algarra">S. Martin-Algarra</name></noRegion></country><country name="Russie"><region name="District fédéral central"><name sortKey="Demidov, L V" sort="Demidov, L V" uniqKey="Demidov L" first="L V" last="Demidov">L V Demidov</name></region></country><country name="Allemagne"><region name="Bavière"><name sortKey="K Mpgen, E" sort="K Mpgen, E" uniqKey="K Mpgen E" first="E" last="K Mpgen">E. K Mpgen</name></region><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><name sortKey="Mauch, C" sort="Mauch, C" uniqKey="Mauch C" first="C" last="Mauch">C. Mauch</name></country><country name="Pologne"><noRegion><name sortKey="Karaszewska, B" sort="Karaszewska, B" uniqKey="Karaszewska B" first="B" last="Karaszewska">B. Karaszewska</name></noRegion><name sortKey="Rutkowski, P" sort="Rutkowski, P" uniqKey="Rutkowski P" first="P" last="Rutkowski">P. Rutkowski</name></country><country name="Canada"><region name="Québec"><name sortKey="Miller, W H" sort="Miller, W H" uniqKey="Miller W" first="W H" last="Miller">W H Miller</name></region></country><country name="Australie"><noRegion><name sortKey="Millward, M" sort="Millward, M" uniqKey="Millward M" first="M" last="Millward">M. Millward</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Chiarion Sileni, V" sort="Chiarion Sileni, V" uniqKey="Chiarion Sileni V" first="V" last="Chiarion-Sileni">V. Chiarion-Sileni</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003647 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003647 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24769640
|texte= Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24769640" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |